Similar studies for GEO DataSets (Select 200017630) - GEO DataSets

Select item 2000176301.

HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib

(Submitter supplied) HER2 targeting with trastuzumab has changed the prognosis of breast cancer patients carrying amplification and/or overexpression of this oncogene. Despite this progress, however, resistance to trastuzumab occurs in the vast majority of patients. Newer anti-HER2 therapies, like the dual tyrosine-kinase inhibitor (TKI) lapatinib, show antitumor activity in a limited proportion of patients, indicating that HER2 can be still exploited as a target after trastuzumab failure. more...

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL4133
2 Samples

Download data: TXT

Series

Accession:: GSE17630

ID:: 200017630

Select item 2000184962.

Breast Cell Lines: Experimental vs. Mixed Reference

(Submitter supplied) Transcriptional profiling of breast cell lines comparing breast cell line mixed reference with individual breast cell lines. Goal was to characterize breast cell line subtypes.

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL7264
51 Samples

Download data: TXT

Series

Accession:: GSE18496

ID:: 200018496

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 2000161793.

BT474 and BT474-J4 microarray data

(Submitter supplied) These data provide scientific information to understand the mechanism of action of lapatinib resistance in HER2-positive patients and to test the combination of HER2-targeted agents and GSK1363089 (foretinib) in the clinic by using an acquired lapatinib-resistant cell line.

Organism:: Homo sapiens

Type:: Expression profiling by array

Dataset:: GDS4083
Platform:: GPL570
18 Samples

Download data: CEL

Series

Accession:: GSE16179

ID:: 200016179

Select item 2000078224.

A comparison of DNA copy number profiling platforms using a panel of melanoma cell lines

(Submitter supplied) The accurate mapping of recurring DNA copy number aberrations (CNAs), a hallmark feature of the cancer genome, has facilitated the discovery of tumor suppressor genes and oncogenes. Microarray-based assays designed to detect these chromosomal copy number alterations on a genome-wide and high-resolution scale have emerged as a cornerstone technology in the genomic era. The diversity of commercially-available platforms prompted a systematic comparison of five copy number profiling assays for their ability to detect 2-fold copy number gain and loss (4n or 1n, respectively) as well as focal high-amplitude CNAs. more...

Organism:: Homo sapiens

Type:: Genome variation profiling by genome tiling array; Genome variation profiling by SNP array

8 related Platforms
151 Samples

Download data: CEL, TXT

Series

Accession:: GSE7822

ID:: 200007822

Select item 40835.

Lapatinib-resistant HER2-positive breast tumor cells

Analysis of BT474 (lapatinib-sensitive) and BT474-J4 (acquired lapatinib-resistance) HER2+ breast cancer cells treated with lapatinib, foretinib or both. Foretinib restored lapatinib-sensitivity in BT474-J4. Results provide insight into molecular basis of acquired lapatinib-resistance in BC cells.

Organism:: Homo sapiens

Type:: Expression profiling by array, count, 4 agent, 2 cell line, 2 genotype/variation sets

Platform:: GPL570
Series:: GSE16179
18 Samples

Download data: CEL

DataSet

Accession:: GDS4083

ID:: 4083

Select item 2000310606.

Gene expression analysis of Hodgkin lymphoma cell lines treated with the AKT inhibitor perifosine and the multikinase inhibitor sorafenib

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL6947
60 Samples

Download data

Series

Accession:: GSE31060

ID:: 200031060

Select item 2000310597.

Gene expression profiling of L-540 Hodgkin lymphoma cell line after in vitro and in vivo treatment with perifosine in combination with sorafenib

(Submitter supplied) Three HL cell lines (HD-MyZ, L-540 and HDLM-2) were used to investigate the effects of perifosine and sorafenib using in vitro assays analyzing cell growth, cell cycle distribution, gene expression profiling (GEP), and apoptosis. Western blotting (WB) experiments were performed to determine whether the two-drug combination affected MAPK and PI3K/AKT pathways as well as apoptosis. Additionally, the antitumor efficacy and mechanism of action of perifosine/sorafenib combination were investigated in vivo in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice using tumor growth rates and survival as endpoints. more...

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL6947
12 Samples

Download data: TXT

Series

Accession:: GSE31059

ID:: 200031059

Select item 2000310588.

Gene expression profiling of HD-MyZ Hodgkin lymphoma cell line after in vitro and in vivo treatment with perifosine in combination with sorafenib

(Submitter supplied) Three HL cell lines (HD-MyZ, L-540 and HDLM-2) were used to investigate the effects of perifosine and sorafenib using in vitro assays analyzing cell growth, cell cycle distribution, gene expression profiling (GEP), and apoptosis. Western blotting (WB) experiments were performed to determine whether the two-drug combination affected MAPK and PI3K/AKT pathways as well as apoptosis. Additionally, the antitumor efficacy and mechanism of action of perifosine/sorafenib combination were investigated in vivo in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice using tumor growth rates and survival as endpoints. more...

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL6947
12 Samples

Download data: TXT

Series

Accession:: GSE31058

ID:: 200031058

Select item 2000310579.

Gene expression profiling of HDLM-2 Hodgkin lymphoma cell line after in vitro and in vivo treatment with perifosine in combination with sorafenib

(Submitter supplied) Three HL cell lines (HD-MyZ, L-540 and HDLM-2) were used to investigate the effects of perifosine and sorafenib using in vitro assays analyzing cell growth, cell cycle distribution, gene expression profiling (GEP), and apoptosis. Western blotting (WB) experiments were performed to determine whether the two-drug combination affected MAPK and PI3K/AKT pathways as well as apoptosis. Additionally, the antitumor efficacy and mechanism of action of perifosine/sorafenib combination were investigated in vivo in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice. more...

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL6947
12 Samples

Download data: TXT

Series

Accession:: GSE31057

ID:: 200031057

Select item 20007390010.

Gene Regulation by microRNA-16 forced expression in ErbB-2 positive murine breast cancer cells.

(Submitter supplied) miR-16 is a potent tumor suppressor in ErbB-2 positive breast cancer. The primary objetive of this study was to identify previously uncharacterized putative mRNA targets of miR-16 in ErbB-2 postitive breast cancer cells. To achieve our objective we studied the effects of exogenously expressed miR-16 on the gene expression profile of primary cultures of ErbB-2 positive murine breast cancer tumors. The C4HD tumor line displays high levels of estrogen receptor and progesterone receptor, overexpresses ErbB-2 and ErbB-3, exhibits low ErbB-4 levels, and lacks EGF-R expression.

Organism:: Mus musculus

Type:: Expression profiling by array

Platform:: GPL7202
6 Samples

Download data: TXT

Series

Accession:: GSE73900

ID:: 200073900

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 20008360811.

SNP arrays of BT474 Latpatinib and/or Trastuzumab resistant cell lines for copy number analysis.

(Submitter supplied) Targeting HER2 with lapatinib (L), trastuzumab (T), or the LT combination, is effective in HER2+ breast cancer (BC), but de novo and acquired resistance commonly occur. The purpose of this experiment was to investigate the somatic alterations found in Lapatinib and/or Trastuzumab resistant cells lines.

Organism:: Homo sapiens

Type:: Genome variation profiling by SNP array; SNP genotyping by SNP array

Platform:: GPL16104
4 Samples

Download data: TXT

Series

Accession:: GSE83608

ID:: 200083608

PubMed Full text in PMC Similar studies

Select item 20014638012.

RNA sequencing of trastuzumab plus pertuzumab-refractory tumor in a mouse xenograft model

(Submitter supplied) We report RNA sequencing data of trastuzumab plus pertuzumab-refractory tumor in a mouse xenograft model.

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing

Platform:: GPL24676
2 Samples

Download data: TXT

Series

Accession:: GSE146380

ID:: 200146380

PubMed Full text in PMC Similar studies SRA Run Selector

Select item 20014630713.

RNA sequencing of T-DM1-refractory tumor in a mouse xenograft model

(Submitter supplied) We report RNA sequencing data of T-DM1-refractory tumor in a mouse xenograft model.

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing

Platform:: GPL24676
2 Samples

Download data: TXT

Series

Accession:: GSE146307

ID:: 200146307

PubMed Full text in PMC Similar studies Analyze with GEO2R SRA Run Selector

Select item 20013078814.

A Phase II Randomized Trial of Neoadjuvant Trastuzumab or Lapatinib or the Combination of Trastuzumab and Lapatinib, Followed by Docetaxel and Carboplatin with Trastuzumab and/or Lapatinib in Patients with HER2+ Breast Cancer

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL6480
199 Samples

Download data: TXT

Series

Accession:: GSE130788

ID:: 200130788

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 20013078715.

A Phase II Randomized Trial of Neoadjuvant Trastuzumab or Lapatinib or the Combination of Trastuzumab and Lapatinib, Followed by Docetaxel and Carboplatin with Trastuzumab and/or Lapatinib in Patients with HER2+ Breast Cancer [treatments]

(Submitter supplied) Adjuvant docetaxel, carboplatin, and trastuzumab (TCH) is a standard regimen for HER2+ breast cancer. Dual HER2-blockade with lapatinib (L) and trastuzumab demonstrated significant activity in the metastatic and neoadjuvant settings. This study evaluates neoadjuvant TC plus trastuzumab (H) and/or lapatinib (L). This study demonstrated a similar pCR rate with TCH and TCHL and a lower rate of pCR with TCL. more...

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL6480
89 Samples

Download data: TXT

Series

Accession:: GSE130787

ID:: 200130787

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 20013078616.

A Phase II Randomized Trial of Neoadjuvant Trastuzumab or Lapatinib or the Combination of Trastuzumab and Lapatinib, Followed by Docetaxel and Carboplatin with Trastuzumab and/or Lapatinib in Patients with HER2+ Breast Cancer [Baseline]

(Submitter supplied) Adjuvant docetaxel, carboplatin, and trastuzumab (TCH) is a standard regimen for HER2+ breast cancer. Dual HER2-blockade with lapatinib (L) and trastuzumab demonstrated significant activity in the metastatic and neoadjuvant settings. This study evaluates neoadjuvant TC plus trastuzumab (H) and/or lapatinib (L). This study demonstrated a similar pCR rate with TCH and TCHL and a lower rate of pCR with TCL. more...

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL6480
110 Samples

Download data: TXT

Series

Accession:: GSE130786

ID:: 200130786

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 20012925417.

Pertubations of gene expresion by lapatinib or THZ1 in HER2 positive breast cancer cell lines.

(Submitter supplied) Gene expression profiling were examined by Human HT-12 v4.0 Expression BeadChip arrays in SKBR3 and BT474 cells treated with HER2 inhibitor lapatinib or CDK7 inhibitor THZ1.

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL10558
18 Samples

Download data: IDAT

Series

Accession:: GSE129254

ID:: 200129254

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 20012787618.

Transcriptomic changes driven by oncogenic kinases

(Submitter supplied) Transcriptomic changes were compared by RNA-seq in human mammary epithelial cells (HMECs) with or without ectopic expression of oncogenic kinase HER2, PI3KCA(mut), or SHP(mut).

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing

Platform:: GPL16791
12 Samples

Download data: TXT

Series

Accession:: GSE127876

ID:: 200127876

PubMed Full text in PMC Similar studies Analyze with GEO2R SRA Run Selector

Select item 20013205519.

Targeting the mevalonate pathway to overcome acquired anti-HER2 treatment resistance in breast cancer [RNA-seq]

(Submitter supplied) Despite effective strategies, therapy resistance in HER2+ breast cancer remains a challenge. While the Mevalonate pathway (MVA) is suggested to promote cell growth and survival, including in HER2+ models, its potential role in resistance to HER2-targeted therapy is unknown. Using HER2+ breast cancer parental (P) cell models (AU565, SKBR3, and UACC812), we have established anti-HER2-resistant derivatives made resistant to lapatinib (LR) or lapatinib plus trastuzumab (LTR). more...